Expanding HLA-A*02 Subtype Coverage — Now Available!

We now offer five additional HLA-A*02 subtypes—critical tools for researchers aiming to extend clinical reach beyond A*02:01.

• While HLA-A*02:01 is the most studied and prevalent allele in the U.S. and globally, it doesn’t capture the full diversity of patient populations.
• Many A02:01-restricted peptides also bind other subtypes, making cross-subtype validation a smart strategy for expanding therapeutic access.
• Use our FP-based peptide binding service at peptide-epitope-validation or request custom-engineered HLA-peptide complexes at hla-peptide complex-engineering to test your candidates across multiple A*02 subtypes.

Maximize population coverage. Strengthen your translational pipeline.

To order all 6 A*02 subtypes, please email us for a discounted quote.